Multitasking of the 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor: Beyond cardiovascular diseases

被引：6

作者：

Calabro P. ^{[1
]}

Yeh E.T.H. ^{[1
]}

机构：

[1] Department of Cardiology, Univ. Texas-MD Anderson Cancer Ctr., Houston, TX 77030-4095

来源：

Current Atherosclerosis Reports | 2004年 / 6卷 / 1期

关键词：

Acute Myeloid Leukemia; Statin; Simvastatin; Pravastatin; Lovastatin;

D O I：

10.1007/s11883-004-0114-6

中图分类号：

学科分类号：

摘要：

Statins can profoundly affect cellular metabolism by inhibiting 3-hydroxy-3-methylglutaryl coenzyme A reductase, which is the rate-limiting enzyme responsible for cholesterol synthesis. Many physicians prescribe statins to lower plasma cholesterol levels, which has beneficial effects in both the primary and secondary prevention of coronary artery disease. However, in vitro, in vivo, animal, and clinical studies have all shown that statins may also have important pleiotropic properties. In fact, a number of clinical studies have suggested that statins are involved in modulating diseases such as cancer, osteoporosis, and dementia (including Alzheimer's disease). However, because these studies have been only preliminary and observational in nature, large randomized, placebo-controlled studies are needed to confirm the modulatory role of statins in these important diseases. Copyright © 2004 by Current Science Inc.

引用

页码：36 / 41

页数：5

共 57 条

[41] Rao S., Lowe M., Herliczek T.W., Et al., Lovastatin mediated G1 arrest in normal and tumor breast cells is through inhibition of CDK2 activity and redistribution of p21 and p27, independent of p53, Oncogene, 17, pp. 2393-2402, (1998)
[42] Wachtershauser A., Akoglu B., Stein J., HMG-CoA reductase inhibitor mevastatin enhances the growth inhibitory effect of butyrate in the colorectal carcinoma cell line Caco-2, Carcinogenesis, 22, pp. 1061-1067, (2001)
[43] Rao S., Porter D.C., Chen X., Et al., Lovastatin-mediated G1 arrest is through inhibition of the proteasome, independent of hydroxymethyl glutaryl-CoA reductase, Proc. Natl. Acad. Sci. U.S.A., 96, pp. 7797-7802, (1999)
[44] Newman A., Clutterhuck R.D., Powles R.L., Et al., Selective inhibition of primary acute myeloid leukaemia cell growth by simvastatin, Leukemia, 8, pp. 2023-2029, (1994)
[45] Dimitroulakos J., Ye L.Y., Benzaquen M., Et al., Differential sensitivity of various pediatric cancers and squamous cell carcinomas to lovastatin-induced apoptosis: Therapeutic implications, Clin. Cancer Res., 7, pp. 158-167, (2001)
[46] Dimitroulakos J., Nohynek D., Backway K.L., Et al., Increased sensitivity of acute myeloid leukemias to lovastatin-induced apoptosis: A potential therapeutic approach, Blood, 93, pp. 1308-1318, (1999)
[47] van Beek E., Lowik C., van der Pluijm G., Et al., The role of geranylgeranylation in bone resorption and its suppression by bisphosphonates in fetal bone explants in vitro: A clue to the mechanism of action of nitrogen-containing bisphosphonates, J. Bone Miner. Res., 14, pp. 722-729, (1999)
[48] Luckman S.P., Hughes D.E., Coxon F.P., Et al., Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras, J. Bone Miner. Res., 13, pp. 581-589, (1998)
[49] Edwards C.J., Hart D.J., Spector T.D., Oral statins and increased bone-mineral density in postmenopausal women, Lancet, 355, pp. 2218-2219, (2000)
[50] Wada Y., Nakamura Y., Koshiyama H., Lack of positive correlation between statin use and bone mineral density in Japanese subjects with type 2 diabetes, Arch. Intern. Med., 160, (2000)

← 1 2 3 4 5 6 →